Ipreo Holdings LLC Upgraded To 'B+' On Lower Leverage; Outlook Stable Feb 13

  • ID: 2403905
  • February 2013
  • Standard & Poors
1 of 3

U.S. financial services software provider Ipreo Holdings LLC's operating performance has continued to be strong and leverage has come down, both of which we expect are sustainable trends. Ipreo recently announced the acquisition of DebtDomain, expanding the company's reach into leveraged loans. We are raising our corporate credit rating on the company to 'B+' from 'B'. The rating outlook is stable. The stable outlook reflects our view that the company will continue to grow EBITDA and market share, and that leverage will remain below 5.5x. CHICAGO (Standard & Poor's) Feb. 11, 2013--Standard & Poor's Ratings Services today raised its corporate credit rating on New York-based financial services software provider Ipreo Holdings LLC to 'B+' from 'B'. The outlook is stable....

Companies mentioned in this report are:
- Ipreo Holdings LLC

Action: Upgraded

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Ipreo Holdings LLC

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.